종양 절제 시장 : 기술별(고주파, 마이크로파, 동결 절제, HIFU), 제품별(시스템, 소모품), 용도별(간암, 폐암, 신장암, 골암), 시술별(외과수술, 복강경 수술, 경피적 시술), 최종사용자별 - 세계 예측(-2031년)

The global tumor ablation market is projected to reach USD 1.89 billion by 2031 from USD 1.10 billion in 2026, at a CAGR of 11.4% during the forecast period.

There is notable growth in the market for tumor ablation owing to the increase in the burden of cancer across the globe as well as the rise in demand for minimally invasive treatment methods. With the rising number of cases of liver, lung, kidney, bone, and prostate cancer, there is increased adoption of tumor ablation as an effective alternative or supplement to surgical treatment. Tumor ablation provides numerous benefits in clinical practice, including reduced hospital stay, quicker recovery time, minimized blood loss, reduced complications, and minimal damage to healthy tissue; thus, this procedure is ideal for people who cannot undergo surgical removal of tumors. Moreover, advances in tumor ablation technology, including radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, laser ablation, high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE), have enhanced the accuracy, safety, and effectiveness of this method. The expansion of oncology and interventional radiology centers, increasing knowledge among physicians, favorable reimbursement policies in developed countries, and investment in cancer care infrastructure facilities have been driving the adoption of tumor ablation devices and market growth.

"By application, the liver cancer segment is expected to have the largest market share in the tumor ablation market."

The largest segment in the tumor ablation market by application is that of liver cancer since a considerable number of ablations are performed to treat both primary liver cancers and some cases of metastatic liver lesions. It has been established that tumor ablation serves as the treatment method of choice for patients with small, localized tumors where surgery and liver transplantation are contraindicated due to compromised liver functionality or other reasons. Technologies like RFA, MWA, cryoablation, and IRE are extensively used to eliminate liver tumors because they ensure tumor elimination while preserving healthy liver tissue. Also, the growth in the incidence of liver cancer around the world, increasing preference towards minimal invasiveness of the procedure, the efficacy proven by tumor ablation in case of early-stage HCC, and development of interventional oncology centers are among other factors contributing to the dominant position of the liver cancer segment in the global tumor ablation market.

"By end user, the hospitals & clinics segment is expected to hold the largest market share in the tumor ablation market."

Hospitals and clinics constitute the highest segment of the tumor ablation market based on end-user owing to their advanced capabilities to provide comprehensive cancer care, well-equipped procedural infrastructure, and multidisciplinary oncological teams. Hospitals and clinics possess all necessary operating rooms and interventional radiology units along with trained and skilled personnel who can conduct a large number of tumor ablation procedures with ease. Hospitals and clinics treat a vast number of cancer cases that require combination therapies such as surgery, chemotherapy, radiation therapy, and ablation. Favorable reimbursement scenarios, advanced ablation technologies, and infrastructure development in the field of oncology have further boosted the adoption of tumor ablation devices in such healthcare settings. An increase in the number of minimally invasive cancer procedures conducted in hospitals and clinics has led to their increased presence in the tumor ablation market.

"US to grow at the highest CAGR for North America tumor ablation market."

US is estimated to witness the fastest CAGR in the North American market for tumor ablation owing to factors such as increasing cases of cancer, rising number of minimally invasive procedures, and development in ablation technology. This region enjoys an advanced healthcare system, presence of top players manufacturing medical devices, and faster adoption of latest technologies such as microwave ablation, cryoablation, irreversible electroporation (IRE), and HIFU. Other factors boosting the growth of the market include investments in cancer research, increasing interventional oncology programs, and an increasing number of specialty cancer centers. Favorable reimbursement scenarios, high healthcare spending, clinical trials, and awareness among doctors and patients about the benefits of tumor ablation are other factors that will boost adoption of tumor ablation devices, making the US the fastest-growing market in North America.

A breakdown of the primary participants (supply-side) for the tumor ablation market referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3-25%
• By Designation: C-level-45%, Director Level-35%, and Others-20%
• By Region: North America-27%, Europe-25%, Asia Pacific-30%, Latin America- 8%, Middle East & Africa-10% .

Prominent players in the tumor ablation market are Medtronic (Ireland), Boston Scientific Corporation (US), EDAP TMS (France), Bioventus Inc. (US), CONMED Corporation (US).

Research Coverage:

The report analyzes the tumor ablation market and aims to estimate the market size and future growth potential of this market based on various segments such as technology, product, procedure, application, end user, and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall tumor ablation market. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

• Analysis of key drivers (" Increasing global cancer incidence, Rising preference for minimally invasive procedures, Growing geriatric population, Rapid technological advancement), (High Cost of Tumor Ablation Systems and Procedures, Stringent Regulatory Approval Pathways), opportunities (Expansion of Cancer Care Centers and Hospitals, Adoption of Robotic and Al-Assisted Ablation Technologies) and challenges (Shortage of Skilled Interventional Radiologists and Oncologists, Budget Limitations in Hospitals).
• Market Penetration: It includes extensive information on products offered by the major players in the global tumor ablation market. The report includes various segments in technology, product, procedure, application, end user, and region.
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global tumor ablation market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by technology, product, procedure, application, end user, and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global tumor ablation market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, product offerings, and capacities of the major competitors in the global tumor ablation market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONS CONSIDERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 REGIONAL SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 TUMOR ABLATION MARKET OVERVIEW
• 3.2 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT AND COUNTRY (2025)
• 3.3 TUMOR ABLATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES (2025)
• 3.4 TUMOR ABLATION MARKET, BY REGION (2024-2031)
• 3.5 TUMOR ABLATION MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
  • 4.1.1 DRIVERS
    • 4.1.1.1 Increasing global cancer incidence
    • 4.1.1.2 Rising preference for minimally invasive procedures
    • 4.1.1.3 Growing geriatric population
    • 4.1.1.4 Rapid technological advancement
  • 4.1.2 RESTRAINTS
    • 4.1.2.1 High cost of tumor ablation systems and procedures
    • 4.1.2.2 Stringent regulatory approval pathways
  • 4.1.3 OPPORTUNITIES
    • 4.1.3.1 Expansion of cancer care centers and hospitals
    • 4.1.3.2 Adoption of robotic and AI-assisted ablation technologies
  • 4.1.4 CHALLENGES
    • 4.1.4.1 Shortage of skilled interventional radiologists and oncologists
    • 4.1.4.2 Budget limitations in hospitals
• 4.2 UNMET NEEDS AND WHITE SPACES
  • 4.2.1 UNMET NEEDS IN TUMOR ABLATION MARKET
  • 4.2.2 WHITE SPACE OPPORTUNITIES
• 4.3 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.3.1 INTERCONNECTED MARKETS
  • 4.3.2 CROSS-SECTOR OPPORTUNITIES MARKET
• 4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL ABLATION TECHNOLOGY INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL INTERVENTIONAL ONCOLOGY INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
  • 5.4.1 RESEARCH & PRODUCT DEVELOPMENT
  • 5.4.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
  • 5.4.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS (2023-2025)
  • 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER (2025)
  • 5.6.2 AVERAGE SELLING PRICE TREND, BY REGION (2023-2025)
• 5.7 TRADE DATA ANALYSIS
  • 5.7.1 IMPORT SCENARIO FOR HS CODE 9018
  • 5.7.2 EXPORT SCENARIO FOR HS CODE 9018
• 5.8 KEY CONFERENCES AND EVENTS, 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.10 INVESTMENT AND FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 CASE STUDY 1: RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY
  • 5.11.2 CASE STUDY 2: RADIOFREQUENCY ABLATION ANALYSIS
  • 5.11.3 CASE STUDY 3: ABLATION OF LOCALIZED RENAL TUMOR
• 5.12 IMPACT OF 2025 US TARIFFS-TUMOR ABLATION MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON COUNTRIES/REGIONS
    • 5.12.4.1 US
    • 5.12.4.2 Europe
    • 5.12.4.3 Asia Pacific
  • 5.12.5 IMPACT ON END-USER INDUSTRIES
    • 5.12.5.1 Hospitals & clinics
    • 5.12.5.2 Cancer care centers
    • 5.12.5.3 Ambulatory surgical centers and outpatient facilities
    • 5.12.5.4 Interventional radiology and specialty oncology clinics
    • 5.12.5.5 Academic medical centers and research institutions
    • 5.12.5.6 Public and government-funded healthcare facilities

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 RADIOFREQUENCY ABLATION (RFA)
  • 6.1.2 MICROWAVE ABLATION (MWA)
  • 6.1.3 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 ROBOTIC-ASSISTED NAVIGATION
  • 6.2.2 AI-ASSISTED TREATMENT PLANNING
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 TUMOR EMBOLIZATION
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.4.1 SHORT-TERM (2025-2027) | FOUNDATION & EARLY COMMERCIALIZATION
  • 6.4.2 MID-TERM (2027-2030) | EXPANSION & STANDARDIZATION
  • 6.4.3 LONG-TERM (2030-2035+) | MASS COMMERCIALIZATION & DISRUPTION
• 6.5 PATENT ANALYSIS
• 6.6 FUTURE APPLICATIONS OF TUMOR ABLATION
• 6.7 IMPACT OF AI/GEN AI-TUMOR ABLATION MARKET
  • 6.7.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.7.2 BEST PRACTICES IN TUMOR ABLATION PROCESSING
  • 6.7.3 CASE STUDIES OF AI IMPLEMENTATION IN TUMOR ABLATION MARKET
  • 6.7.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS
  • 6.7.5 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN TUMOR ABLATION MARKET

7 REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
    • 7.1.2.1 North America
      • 7.1.2.1.1 US
      • 7.1.2.1.2 Canada
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
      • 7.1.2.3.1 Japan
      • 7.1.2.3.2 China
      • 7.1.2.3.3 India
    • 7.1.2.4 Latin America
      • 7.1.2.4.1 Brazil
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY
  • 8.5.1 REVENUE POTENTIAL
  • 8.5.2 COST DYNAMICS
  • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 TUMOR ABLATION MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 RADIOFREQUENCY ABLATION
  • 9.2.1 LOW COST OF RADIOFREQUENCY ABLATION TO CONTRIBUTE TO MARKET GROWTH
• 9.3 MICROWAVE ABLATION
  • 9.3.1 ADVANTAGES OF MICROWAVE ABLATION TO BOOST MARKET GROWTH
• 9.4 CRYOABLATION
  • 9.4.1 HIGH SAFETY AND EFFICACY OF CRYOABLATION TO BOOST MARKET
• 9.5 IRREVERSIBLE ELECTROPORATION
  • 9.5.1 NON-THERMAL ABLATION AND PRECISION TREATMENT CAPABILITIES OF IRREVERSIBLE ELECTROPORATION TO DRIVE MARKET GROWTH
• 9.6 OTHER TECHNOLOGIES

10 TUMOR ABLATION MARKET, BY PRODUCT TYPE

• 10.1 INTRODUCTION
• 10.2 SYSTEMS
  • 10.2.1 RADIOFREQUENCY ABLATION SYSTEMS
    • 10.2.1.1 Advancements In Radiofrequency Ablation Systems To Enhance Precision and Treatment Efficacy
  • 10.2.2 MICROWAVE ABLATION SYSTEMS
    • 10.2.2.1 Advancements in high-power energy delivery and larger ablation zones to drive microwave ablation systems market growth
  • 10.2.3 IRREVERSIBLE ELECTROPORATION SYSTEMS
    • 10.2.3.1 Non-thermal ablation and precision treatment capabilities of irreversible electroporation to drive market growth
  • 10.2.4 CRYOABLATION SYSTEMS
    • 10.2.4.1 Advancements in controlled freezing and ablation-zone visualization to drive cryoablation systems market growth
  • 10.2.5 OTHER SYSTEMS
• 10.3 CONSUMABLES & ACCESSORIES
• 10.4 PROBES/ELECTRODES
  • 10.4.1 RADIOFREQUENCY ABLATION PROBES
    • 10.4.1.1 Advancements in RFA probe design and cooling technologies to drive market growth
  • 10.4.2 MICROWAVE ABLATION PROBES
    • 10.4.2.1 Advancements in microwave antenna design and energy delivery to support market growth
  • 10.4.3 OTHER PROBES/ELECTRODES
• 10.5 OTHER CONSUMABLES & ACCESSORIES

11 TUMOR ABLATION MARKET, BY PROCEDURE

• 11.1 INTRODUCTION
• 11.2 SURGICAL ABLATION
  • 11.2.1 RISING UTILIZATION OF SURGICAL ABLATION IN END-USER FACILITIES TO PROPEL MARKET
• 11.3 LAPAROSCOPIC ABLATION
  • 11.3.1 IMPROVED SUCCESS RATE AND REAL-TIME VISUALIZATION TO BOOST DEMAND
• 11.4 PERCUTANEOUS ABLATION
  • 11.4.1 SHORTER RECOVERY TIME AND COST-EFFECTIVENESS OF PROCEDURE TO DRIVE SEGMENT

12 TUMOR ABLATION MARKET, BY APPLICATION

• 12.1 INTRODUCTION
• 12.2 LIVER CANCER
  • 12.2.1 PROMISING OUTCOMES OF ABLATION IN TREATING HCC TO DRIVE MARKET
• 12.3 LUNG CANCER
  • 12.3.1 RISING INCIDENCE OF LUNG CANCER TO FUEL MARKET
• 12.4 KIDNEY CANCER
  • 12.4.1 RISING PREVALENCE OF KIDNEY CANCER AND MINIMAL DAMAGE TO HEALTHY TISSUE TO DRIVE ADOPTION
• 12.5 BONE CANCER
  • 12.5.1 RISING USE OF ABLATION TECHNIQUES TO TREAT OSTEOID OSTEOMA TO BOOST GROWTH
• 12.6 OTHER APPLICATIONS

13 TUMOR ABLATION MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 HOSPITALS & CLINICS
  • 13.2.1 INCREASING ADOPTION OF ADVANCED TUMOR ABLATION SYSTEMS TO PROPEL MARKET
• 13.3 CANCER CARE CENTERS
  • 13.3.1 GROWING ESTABLISHMENT OF CANCER CARE CENTERS TO FUEL MARKET
• 13.4 AMBULATORY SURGERY CENTERS
  • 13.4.1 SHIFT TOWARD MINIMALLY INVASIVE AND OUTPATIENT PROCEDURES TO DRIVE MARKET
• 13.5 OTHER END USERS

14 TUMOR ABLATION MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 US
    • 14.2.1.1 Rising prevalence of cancer to propel market growth
  • 14.2.2 CANADA
    • 14.2.2.1 Growing burden of cancer to support market growth
• 14.3 EUROPE
  • 14.3.1 GERMANY
    • 14.3.1.1 Highly developed healthcare infrastructure and rising disease incidence to ensure strong growth prospects
  • 14.3.2 FRANCE
    • 14.3.2.1 Growing geriatric population to support market growth in France
  • 14.3.3 UK
    • 14.3.3.1 Growing target patient population to support market growth in UK
  • 14.3.4 ITALY
    • 14.3.4.1 Rising awareness to support market growth
  • 14.3.5 SPAIN
    • 14.3.5.1 Increasing government funding for research to support market growth
  • 14.3.6 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 JAPAN
    • 14.4.1.1 Presence of universal healthcare reimbursement scenario to drive market growth
  • 14.4.2 CHINA
    • 14.4.2.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth
  • 14.4.3 INDIA
    • 14.4.3.1 Ongoing modernization and infrastructure development in India to support market growth
  • 14.4.4 AUSTRALIA
    • 14.4.4.1 Rising research investments and awareness campaigns to support market growth
  • 14.4.5 SOUTH KOREA
    • 14.4.5.1 Rising R&D and promising clinical trials to positively impact market growth
  • 14.4.6 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 BRAZIL
    • 14.5.1.1 Modernization of healthcare facilities in Brazil to boost market
  • 14.5.2 MEXICO
    • 14.5.2.1 Availability of advanced care and increasing awareness programs to fuel market growth in Mexico
  • 14.5.3 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST & AFRICA
  • 14.6.1 GCC COUNTRIES
    • 14.6.1.1 Increasing investments in oncology infrastructure and adoption of advanced minimally invasive treatment technologies to drive market growth
  • 14.6.2 REST OF MIDDLE EAST AND AFRICA

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TUMOR ABLATION MARKET
• 15.3 REVENUE ANALYSIS, 2021-2025
• 15.4 MARKET SHARE ANALYSIS, 2025
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Technology footprint
    • 15.5.5.4 Product type footprint
    • 15.5.5.5 Procedure footprint
    • 15.5.5.6 Application footprint
    • 15.5.5.7 End-user footprint
• 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 DYNAMIC COMPANIES
  • 15.6.3 STARTING BLOCKS
  • 15.6.4 RESPONSIVE COMPANIES
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
• 15.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 15.7.1 FINANCIAL METRICS
  • 15.7.2 COMPANY VALUATION
  • 15.7.3 BRAND/PRODUCT COMPARISON
• 15.8 COMPETITIVE SCENARIO
  • 15.8.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS
  • 15.8.2 DEALS
  • 15.8.3 EXPANSIONS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 MEDTRONIC
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product approvals
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Key strengths
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses and competitive threats
  • 16.1.2 BOSTON SCIENTIFIC CORPORATION
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products offered
    • 16.1.2.3 MnM view
      • 16.1.2.3.1 Key strengths
      • 16.1.2.3.2 Strategic choices made
      • 16.1.2.3.3 Weaknesses and competitive threats
  • 16.1.3 EDAP TMS S.A.
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products offered
    • 16.1.3.3 MnM view
      • 16.1.3.3.1 Key strengths
      • 16.1.3.3.2 Strategic choices made
      • 16.1.3.3.3 Weaknesses and competitive threats
  • 16.1.4 BIOVENTUS INC.
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Deals
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Key strengths
      • 16.1.4.4.2 Strategic choices made
      • 16.1.4.4.3 Weaknesses and competitive threats
  • 16.1.5 CONMED CORPORATION
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products offered
    • 16.1.5.3 MnM view
      • 16.1.5.3.1 Key strengths
      • 16.1.5.3.2 Strategic choices made
      • 16.1.5.3.3 Weaknesses and competitive threats
  • 16.1.6 ICECURE MEDICAL LTD.
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Product approvals
      • 16.1.6.3.2 Deals
      • 16.1.6.3.3 Expansions
  • 16.1.7 ANGIODYNAMICS, INC.
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Product launches
      • 16.1.7.3.2 Expansions
      • 16.1.7.3.3 Deals
  • 16.1.8 VARIAN MEDICAL SYSTEMS, INC.
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Product launches
      • 16.1.8.3.2 Deals
  • 16.1.9 STRYKER
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Product approvals
      • 16.1.9.3.2 Expansions
  • 16.1.10 CANYON MEDICAL INC.
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products offered
  • 16.1.11 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products offered
  • 16.1.12 MERIT MEDICAL SYSTEMS, INC.
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Deals
  • 16.1.13 BAIRD MEDICAL INVESTMENT HOLDINGS LTD.
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products offered
    • 16.1.13.3 Recent developments
      • 16.1.13.3.1 Expansions
  • 16.1.14 QUANTUM SURGICAL
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products offered
    • 16.1.14.3 Recent developments
      • 16.1.14.3.1 Deals
  • 16.1.15 THERACLION
    • 16.1.15.1 Business overview
    • 16.1.15.2 Products offered
• 16.2 OTHER PLAYERS
  • 16.2.1 RF MEDICAL CO., LTD.
  • 16.2.2 MINIMAX MEDICAL HOLDING GROUP
  • 16.2.3 MERMAID MEDICAL
  • 16.2.4 MONTERIS
  • 16.2.5 SONABLATE CORP.
  • 16.2.6 ECO MEDICAL
  • 16.2.7 SURGNOVA
  • 16.2.8 STARMED CO., LTD.
  • 16.2.9 CREO MEDICAL
  • 16.2.10 MEDSPHERE SHANGHAI (SUBSIDIARY OF MEDSPHERE INTERNATIONAL, INC.)

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH DATA
  • 17.1.1 SECONDARY DATA
    • 17.1.1.1 Key data from secondary sources
  • 17.1.2 PRIMARY DATA
    • 17.1.2.1 Key data from primary sources
    • 17.1.2.2 Key industry insights
• 17.2 MARKET SIZE ESTIMATION
  • 17.2.1 BOTTOM-UP APPROACH
  • 17.2.2 TOP-DOWN APPROACH
  • 17.2.3 BASE NUMBER ESTIMATION
• 17.3 MARKET FORECAST APPROACH
• 17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 17.5 ASSUMPTIONS
  • 17.5.1 MARKET SHARE ASSUMPTIONS
  • 17.5.2 RESEARCH ASSUMPTIONS
• 17.6 FACTOR ANALYSIS
• 17.7 RISK ASSESSMENT
• 17.8 METHODOLOGY-RELATED LIMITATIONS

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS